Skip to content
PICO Portalanswers from OpenAlex

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint

PaperCitations, authors & open-access status

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint is a paper indexed in PICO Portal from OpenAlex.

How many citations does The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint have?

PICO Portalcitation count

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint has 124 citations in the OpenAlex counts PICO Portal stores.

When was The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint published?

PICO Portalyear

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint has 2023 year in the PICO Portal index.

What is the open-access status of The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint?

PICO Portaloa status

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint has gold oa status in the PICO Portal index.

What is the DOI of The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint?

PICO Portaldoi

The DOI for The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint is on the source record.

What is the PMID of The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint?

PICO Portalpmid

The PMID for The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint is on the source record.

What is the OpenAlex record for The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint?

PICO Portalopenalex

The OpenAlex for The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial